Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By



This article was originally published in The Gray Sheet

Executive Summary

Begins clinical trials of its laser catheter ablation system for percutaneous treatment of ventricular tachycardia. The firm hopes to complete the 10-patient study at the Carolinas Medical Center in Charlotte, North Carolina within a year. Single-center studies also are continuing in idiopathic hypertrophic subaortic stenosis and in open chest surgical ventricular tachycardia. Angeion recently signed an agreement with Siemens Pacesetter under which Siemens gains an exclusive OEM license to Angeion's defibrillator products and non-exclusive OEM license to Angeion's laser catheter cardiac ablation products. The agreement also provides Angeion with a non-exclusive license to Siemens' defibrillator patents. Siemens has made an initial $5 mil. investment in Angeion, which included the purchase of 875,000 shares at $4 per share and a $1.5 mil. 10-year convertible debenture. Siemens may invest up to an additional $3 mil. based on product development milestones.



Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts